Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis
المؤلفون المشاركون
Shih, Vanessa
ten Ham, Renske M.
Bui, Christine T.
Tran, Dan N.
Ting, Jie
Wilson, Leslie
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-06-10
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Purpose.
Two BRAFV600E targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in BRAFV600E patients, a mutation that affects ~50% of patients.
We evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for treatment of metastatic melanoma.
Methods.
A Markov model was developed using a societal perspective.
Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine.
Costs were obtained from literature, national databases, and Medicare fee schedules.
Utilities were obtained from published literature.
Deterministic and probabilistic sensitivity analyses were run to test the impact of uncertainties.
Results.
The incremental cost-effectiveness ratio of dabrafenib was $149,035/QALY compared to dacarbazine.
Vemurafenib was dominated by dabrafenib.
Probabilistic sensitivity analysis showed that, at a willingness-to-pay (WTP) threshold of ≤$100,000/QALY, dacarbazine was the optimal treatment in ~85% of simulations.
At a WTP threshold of ≥$150,000/QALY, dabrafenib was the optimal treatment.
Conclusion.
Compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY.
Dabrafenib is more efficient compared to vemurafenib.
With few treatment options, dabrafenib is an option for qualifying patients if the overall cost of dabrafenib is reduced to $30,000–$31,000 or a WTP threshold of ≥$150,000/QALY is considered.
More comparative data is needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Shih, Vanessa& ten Ham, Renske M.& Bui, Christine T.& Tran, Dan N.& Ting, Jie& Wilson, Leslie. 2015. Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis. Journal of Skin Cancer،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1070247
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Shih, Vanessa…[et al.]. Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis. Journal of Skin Cancer No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1070247
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Shih, Vanessa& ten Ham, Renske M.& Bui, Christine T.& Tran, Dan N.& Ting, Jie& Wilson, Leslie. Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis. Journal of Skin Cancer. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1070247
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1070247
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر